key: cord-0990576-af55ukif
authors: Kim, Min Kyung; Jang, Seongsoo; Na, Sang-Hoon; Bang, Soo-Mee; Kim, Ji Hyun
title: Vaccine-Induced Immune Thrombotic Thrombocytopenia: First Case Report in South Korea
date: 2021-09-17
journal: J Clin Neurol
DOI: 10.3988/jcn.2021.17.4.570
sha: 49e0ac2d11d7abfd2caa2a52ade0352c9ee9406a
doc_id: 990576
cord_uid: af55ukif

nan

Incident VITT has rarely been reported in people who have received vaccinations for COVID-19, with 348 VITT cases among 14.3 million recipients of the AstraZeneca vaccine in the UK and 32 cases among 10.2 million recipients of the Janssen vaccine in the USA reported to date. 3, 4 The AstraZeneca vaccine is offered to people aged ≥30 years in South Korea, consistent with the European guideline based on the risk-benefit assessment of vaccine-induced serious complications and the prevention of COVID-19 infection. As at June 2021, there were 10 suspected cases of VITT out of 7.9 million recipients in South Korea; however, the presence of antibodies against the PF4-heparin complex was not confirmed by the enzymelinked immunosorbent assay in all of the cases. 2 The Greifswald Working Group has recently provided crucial insight into the pathogenetic mechanism that underlies VITT. 5 Similar to heparin-induced thrombocytopenia (HIT), the vaccination using the AstraZeneca and Janssen vaccines is likely to induce the formation of antibodies against platelet antigens through an inflammatory reaction and immune stimulation, culminating in massive platelet aggregation via the Fc receptor. 5 Since the mechanism of VITT closely resembles the specific immunological response of HIT, the guideline advises avoiding the use of heparin and low-molecular-weight heparin preparations in cases of suspected VITT. The use of warfarin should also be avoided in cases of VITT, because it can paradoxically worsen the thrombosis and cause venous limb gangrene and skin necrosis in HIT. Meanwhile, non-heparin anticoagulants such as oral Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban), direct thrombin inhibitors (e.g., argatroban), and fondaparinux are instead recommended for pharmacological thromboprophylaxis. Moreover, high-dose intravenous IgG (1 g/kg for 2 days) should be administered when the platelet count decreases to <50,000/mm 3 or to <100,000/mm 3 with evidence of major bleeding. It is particularly important that platelet transfusion is avoided since it can cause or exacerbate thrombotic conditions. 6 Herein we have reported the first case of VITT in whom clinical and radiological abnormalities of cerebral venous thrombosis were completely reversed by administering an oral anticoagulant. Awareness that COVID-19 vaccines using adenoviral vectors rarely cause VITT would recognize this catastrophic condition and prompt the clinician to commence appropriate treatment and prevent unintentional grave outcomes.

The patient gave written informed consent for his information and CT/ MR images to be published as a case report in a journal.

All data generated or analyzed during the study are included in this published article (and its supplementary information files).

Formal analysis: Seongsoo Jang, Soo-Mee Bang. Supervision: Ji Hyun Kim. Writing-original draft: Min Kyung Kim, Soo-Mee Bang. Writing-review & editing: Ji Hyun Kim. REFERENCES

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Updates on COV-ID-19 incidence and vaccination in Republic of Korea (as of 00:00

Research and analysis: coronavirus vaccine -weekly summary of Yellow Card reporting

Selected adverse events reported after COVID-19 vaccination

Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH

Heparin induced thrombocytopenia: diagnosis and management update

The authors have no potential conflicts of interest to disclose.

None